
Lipigon Q4 2024 - Rights issue funds 2025

Redeye comments on Lipigons third quarter report, including positive phase I results for Leaderna, clinical data from Marea and the rights issue.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lipigon Q4 2024 - Rights issue funds 2025](#)